First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Clinical trial NCT06454266 · COMPLETED

Trial details

NCT number: NCT06454266
Sponsor: Ningbo No. 1 Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma

Start date: 2021-12-28
Primary completion: 2024-06-30
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.